| REVIEW ARTICLE |
|
| Year : 2020 | Volume
: 10
| Issue : 1 | Page : 19-25 |
|
|
Nonarthroplasty management of osteonecrosis of the femoral head
Harrison R Ferlauto1, Evan M Guerrero1, James R Urbaniak1, Grant E Garrigues2
1 Duke University Department of Orthopaedic Surgery, Durham, NC, USA
2 Midwest Orthopaedics at Rush, Rush University Medical Center, Chicago, IL, USA
Correspondence Address:
Mr. Harrison R Ferlauto
Duke University School of Medicine, 8 Searle Center Drive, Durham, NC 27710
USA
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/DORJ.DORJ_8_20
|
|
|
It is estimated that 10,000–20,000 new cases of osteonecrosis of the femoral head (ONFH) are diagnosed annually in the United States. Left untreated, this disease results in progressive collapse of the femoral head and destruction of the hip joint, resulting in the need for total hip arthroplasty (THA). However, in younger patients with ONFH, initial treatment with THA is not a practical option because these patients typically outlive the life of their implant, and thus may require multiple revision operations. Therefore, a variety of nonarthroplasty treatments for ONFH have been developed to slow the progression of disease and prolong the time that a person can go before requiring THA. These nonarthroplasty treatments are grouped into three general categories: Pharmacologic, nonpharmacologic/nonoperative, and operative. However, there is no consensus as to the optimal nonarthroplasty management of ONFH. This article provides a review of the literature regarding nonarthroplasty management of ONFH.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
